Member Info for Buda_

If I were Tim I would have blocked Roobler months ago!
Roobler - what is it that you hope to achieve by spamming the man? Neilin62 has diligently informed the BB of the questions and answers put to the BOD, and given a timescale for expected reply. Just wait for the answer, there's nothing else to be done at this stage

Mmh, having participated in the mess they made of that demerger I'd respectfully suggest no cogs have been turning. On the last TILS investor call it was stated that Accustem will list in 'early 2021'. There was no mention of IPO, incidentally. But if they really were looking to IPO in early '21, which for me must equate to Q1, then they would already need to be far down the path - that would mean legal and financial advisers appointed, due diligence completed, draft prospectus, regulatory approval, preliminary pricing, institutional marketing begun etc etc. To do all that completely under the radar is both difficult, near impossible in fact, and hugely counter productive - nobody markets an IPO silently. So my conclusion remains the same as last month - if Accustem is to list on the London main market in Q1 then it's likely an RTO, not IPO. There is also a possibility of a direct listing (an introduction), but that presumes Accustem does not need to raise capital, which I think it most definitely does. As to the bigger question, i.e. if it is RTO will it be via BOU, I have no idea!

Accustem might still be a possibility; if TILS think they're going to get an IPO together for Accustem in 12 weeks they're dreaming.

A pedant might argue that Accustem is therefore still a possibility; it's no longer part of TILS...

NEW YORK and LONDON - 1 December 2020 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO Dr. Kunwar Shailubhai will host a conference call on Wednesday, 2 December 2020 at 4:15 p.m. ET to provide updates on the Company. Dr Shailubhai will provide updates on the Company's proposed move from AIM to the Standard Segment of the Main Market of the London Stock Exchange, ongoing clinical trials, as well as other recent developments in Tiziana Life Sciences.

Wednesday, 2 December 2020

Time:

4:15 p.m. Eastern Time

Live Call:

+1-877-425-9470 (U.S. Toll-Free) or +1-201-389-0878 (International)

Webcast:

http://public.viavid.com/index.php?id=142634

TILS has stated that it will move from AIM to the main market. That was scheduled for q4,s o time is running out. Accustem was stated to be listing also in q4.. there's no time left for that to be an IPO so it's either RTO or next year. There's an investor call with a director of TILS at 21.15 this evening; the main market move and the future of Accustem are on the agenda.

take YOUR pick, sorry.

see above, it's impossible that it's an IPO in Q4. So it's either an IPO in March-May 2021, an RTO announced in the next few days, or a buyout announced before year-end. Take you pick!

RE an Accustem IPO. It's impossible to complete an IPO in under a month, especially if that month is December. I'm not even going to mention C-19. Realistically an IPO would take minimum of three months to sort out. So if they are sticking to the 'listing in late q4' the only way forward is RTO. Alternatively, there will be no listing at all, which is a possibility. Either way something needs to be communicated, and quickly. AIMHO obviously

Tils stated in the Sept 16 RNS re Accu : "It is intended that Accustem will seek admission to the standard segment of the Official List and admission to trading on the London Stock Exchange plc by way of an IPO in late Q4 2020 ("Accustem Admission") and potentially a dual listing on NASDAQ in 2021."

However, in the next RNS there was no mention of IPO...Oct 27th "[...] on or about the date upon which the new Accustem Shares are admitted to trading on the main market of the London Stock Exchange plc (subject to appropriate regulatory review and approvals). "

Conclusion: I don't know :)